System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Prof Stéphane Dalle is an expert in Dermatology at Centre Léon Bérard (France). As of October 2026, ScienceLeadR ranks Stéphane Dalle in the top 1% of experts worldwide for Skin Neoplasms, Melanoma and Sexually Transmitted Diseases. Stéphane Dalle has authored 724 publications, the most recent in 2026, and is an investigator in 50 clinical trials, 13 of them ongoing. SLR score: 2,887 (community average: 125). How the SLR is computed.

LeadR Profile

Prof Stéphane Dalle Centre Léon Bérard France
2 887 ScienceLeadR Reputation 2887

Unlock

Register Login
Network Map

Dermatology

Subspecialties: Oncology - Hematology - Immunology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 2001 - 2026
Source: PubMed

Centre Léon Bérard

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 724

Citations

Citations: 22 949 1st author: 45 Last author: 118 Unique author: 2

Main journals

Ann Dermatol Venereol 165
J Clin Oncol 47
Br J Dermatol 38
Eur J Cancer 33
Ann Oncol 28

Best Journals

J Clin Oncol 31
Ann Oncol 19
Lancet Oncol 9

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Relatlimab plus nivolumab versus nivolumab for advanced melanoma: 5-year survival and biomarker analyses of the phase 3 RELATIVITY-047 trial.
PMID 42926136 — confidence intervals, safety, molecular biology, melanoma, biomarkers, nivolumab		Nat Med Top journal20260
Lanreotide, a Somatostatin Analogue, in Advanced Merkel Cell Carcinoma: A Prospective Single-Arm Phase II Study.
PMID 42791653 — cells, merkel cells, somatostatin, neoplasms, therapeutics, dermatology, carcinoma, merkel cell		Cancer Med20260
Real-World Use of Adjuvant Nivolumab for Resected Stage III-IV Melanoma: 2-Year Analysis of AdjuMel.
PMID 42667537 — safety, melanoma, nivolumab, therapeutics		Dermatol Ther (Heidelb)20260
Real-world treatment patterns in stage III and IV melanoma patients: insights from a global multi-center chart review study.
PMID 42564088 — melanoma, multiple chronic conditions, immune system diseases, therapeutics		Front Immunol20261
Patients with Cancer and Immune Checkpoint Inhibitor-Induced Rheumatic irAEs Treated by DMARDs: The RHUMICI Single-Centre Retrospective Cohort.
PMID 42512280 — glucocorticoids, safety, pharmaceutical preparations, antirheumatic agents, neoplasms, arthritis, immune checkpoint inhibitors, therapeutics		Cancers (Basel)20260

Clinical Studies 50

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 7

By phase:

Phase 3 16
N/A 14
Phase 2 13
Phase 2/Phase 3 3
Phase 1 2
Phase 1/Phase 2 2

By status:

Recruiting 18
Completed 15
Active not recruiting 12
Unknown 4
Terminated 1

By type:

Interventional 41
Observational 9

By Monocentric/Multicentric:

monocentric 9
multicentric2to4 2
multicentric5to9 8
multicentricup10 31

Main Topics

Cohort/Consortium Investigators 1

Ongoing Clinical Trials

13 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
Phase 3 Study of V940 and Pembrolizumab in Resected Melanoma
2023-503652-27-00 — melanoma, rna, messenger		Phase 3Active not recruiting2023
NEOREM NEO 1 NEOREM Neo adjuvant Immunotherapy Master Trial for Localized Cancers NEO 1 Neo adjuvant immunotherapy in patients with localized melanoma
2025-522127-95-00 — quality of life, disease-free survival, melanoma, neoplasms, immunotherapy, therapeutics		Phase 2Recruiting2026
A Phase 2 Study of PTX 100 Monotherapy in Patients with r r CTCL
2025-521852-45-00 — cells, safety, lymphoma, lymphoma, t-cell, cutaneous, t-lymphocytes, pharmacokinetics, lymphoma, t-cell		Phase 2Recruiting2026
A Study of Subcutaneous Nivolumab Relatlimab FDC in Previously Untreated Metastatic or Unresectable Melanoma (RELATIVITY 127)
2022-500967-11-00 — pharmaceutical preparations, melanoma, nivolumab		Phase 3Recruiting2023
Neo adjuvant Immunotherapy in Patients With Localized Melanoma
NCT07230613 — injections, melanoma, neoplasms, solutions, immunotherapy, neoadjuvant therapy, nivolumab, therapeutics, ipilimumab		Phase 2Recruiting2026

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS